Lv1
40 积分 2021-08-18 加入
Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): a randomised, controlled, phase 3 trial
1个月前
已完结
Teclistamab plus Daratumumab in Relapsed or Refractory Multiple Myeloma
1个月前
已完结
A practical Bayesian design to identify the maximum tolerated dose contour for drug combination trials
1个月前
已完结
Bayesian optimal interval design for dose finding in drug-combination trials
1个月前
已完结
Glofitamab plus gemcitabine and oxaliplatin (GemOx) versus rituximab-GemOx for relapsed or refractory diffuse large B-cell lymphoma (STARGLO): a global phase 3, randomised, open-label trial
2个月前
已完结
Glofitamab plus gemcitabine and oxaliplatin (GemOx) versus rituximab-GemOx for relapsed or refractory diffuse large B-cell lymphoma (STARGLO): a global phase 3, randomised, open-label trial
2个月前
已完结
Preclinical development and a case report of a nanobody-based CLDN18.2 CAR-T IMC002 with reduced on-target off-tumor toxicity
4个月前
已完结
Chimeric Antigen Receptor (CAR) T-Cell Therapy-Induced Cardiotoxicity: A Narrative Review of Mechanisms, Clinical Presentations, and Strategies for Optimization
4个月前
已完结
Intracerebroventricular bivalent CAR T cells targeting EGFR and IL-13Rα2 in recurrent glioblastoma: a phase 1 trial
5个月前
已完结
Advancements in Bispecific Antibodies for Multiple Myeloma: What's New and What Lies Ahead
6个月前
已完结
皖公网安备34019202002308
